10 completed, 3 unknown, 2 not yet recruiting, 2 withdrawn. 19 Phase 2, 6 Phase 1, 2 Phase 3.
Follow Osteo Arthritis Knee: new trials by email Literature Review of Osteo Arthritis Knee trials Research Report on Osteo Arthritis Knee
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis Gene Therapy GNSC-001, Placebo - Knee Arthritis Osteoarthritis, Knee Arthritis, Osteoarthritis | Phase 2 / Phase 3 | Not yet recruiting | Genascence Corporation | 240 | 2027-07-01 | 2026-09-21 |
| Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint StroMel - Osteo Arthritis Knee | Phase 1 / Phase 2 | Not yet recruiting | Akan Biosciences, LLC | 20 | 2025-10-01 | 2025-01-29 |
| The Role of Vitamin K on Knee Osteoarthritis Outcomes Vitamin K1 500 µg, K1 1000 µg, Vitamin K2 (MK-7) 300 µg - Osteo Arthritis Knee | Phase 1 / Phase 2 | Active not recruiting | Boston University | 49 | 2025-06-03 | 2026-09-21 |
| An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint OA-SYS - Osteoarthritis, Osteo Arthritis Knee | Phase 2 | Recruiting | Ageless Biotech, Inc. | 400 | 2025-05-21 | 2025-09-18 |
| Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches - Osteo Arthritis Knee, Arthritis | Phase 2 | Completed | ZetrOZ, Inc. | 307 | 2024-10-01 | 2026-06-30 |
| A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte) - Osteo Arthritis Knee | Phase 1 / Phase 2 | Completed | Cellcolabs Clinical SPV Limited | 12 | 2023-11-07 | 2026-04-16 |
| Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches - Osteo Arthritis Knee, Arthritis | Phase 2 | Completed | ZetrOZ, Inc. | 200 | 2023-06-03 | 2025-05-15 |
| "Ready-to-use" Intra-articular Formulation of Mesenchymal Stromal Cells "Ready to inject" Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product, Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product - Osteo Arthritis Knee | Phase 2 | Unknown | Universidad de los Andes, Chile | 60 | 2023-04-01 | 2023-03-02 |
| Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee LEVI-04, Placebo - Pain, Osteo Arthritis Knee | Phase 2 | Completed | Levicept | 518 | 2022-10-19 | 2025-11-20 |
| Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee Duloxetine 30 MG, Nonsteroidal Antiinflammatory Drug - Osteo Arthritis Knee | Phase 2 | Completed | Hawler Medical University | 200 | 2022-08-20 | 2023-03-14 |
| OA Optimization Program Pilot Trial Alberta Healthy Living Program, Alberta Obesity Centre Program, Osteoarthritis advice - Osteo Arthritis Knee, Osteoarthritis, Knee | Phase 1 / Phase 2 | Unknown | University of Calgary | 70 | 2022-06-28 | 2024-05-22 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis LY3526318, Placebo - Osteoarthritis, Osteo Arthritis Knee | Phase 2 | Completed | Eli Lilly and Company | 160 | 2021-10-12 | 2024-07-17 |
| pAF for the Treatment of Osteoarthritis Amniotic Fluid Injection, Standard of Care - Osteo Arthritis Knee | Phase 1 / Phase 2 | Completed | University of Utah | 60 | 2021-07-08 | 2026-03-27 |
| The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis Metformin, Placebo - Osteo Arthritis Knee | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-02-16 | 2025-07-14 | |
| Intraarticular Leukocyte-rich and Leukocyte-poor PRP for Osteoarthritis of the Knee Leukocyte-rich platelet-rich plasma, Leukocyte-poor platelet-rich plasma, Corticosteroid - Osteo Arthritis Knee | Phase 2 / Phase 3 | Completed | Queen Savang Vadhana Memorial Hospital, Thailand | 93 | 2020-08-03 | 2023-02-21 |
| Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee Concentrated Bone Marrow Aspirate (BMAC), Platelet-Rich Plasma (PRP) - Osteo Arthritis Knee | Phase 2 | Withdrawn | Mayo Clinic | 2019-09-01 | 2019-12-24 | |
| Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods autologous adipose tissue transfer, PRP injections - Osteo Arthritis Knee, Knee Osteoarthritis | Phase 2 | Unknown | Rehasport Clinic | 60 | 2018-07-30 | 2020-03-25 |
| Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis allogenic lyophilized growth factors - Osteo Arthritis Knee | Phase 2 | Completed | Rasmia Elgohary | 31 | 2017-05-01 | 2021-01-28 |
| A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee V120083, Naproxen, Placebo - Osteo Arthritis Knee | Phase 2 | Completed | Purdue Pharma LP | 291 | 2017-03-14 | 2019-02-12 |
Osteoarthritis (9) · Osteoarthritis, Knee (5) · Arthritis (4) · Joint Diseases (3) · Pain (3) · Insomnia, Fatal Familial (1) · Musculoskeletal Diseases (1) · Osteoarthritis, Hip (1) · Rheumatic Diseases (1)
Musculoskeletal Diseases (12) · Joint Diseases (10) · Rheumatic Diseases (10) · Arthritis (9) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Osteoarthritis (2) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Connective Tissue Diseases (1) · Dyssomnias (1) · Infections (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1)
Adrenal Cortex Hormones (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · Duloxetine Hydrochloride (1) · Educational Status (1) · Exercise (1) · MICU1 protein, human (1) · Metformin (1) · Naproxen (1) · Pharmaceutical Preparations (1) · Physical Therapy Modalities (1) · Platelet Activating Factor (1) · Standard of Care (1) · Sugars (1) · Vitamin K 1 (1) · Vitamin K 2 (1)
ZetrOZ, Inc. (2) · Ageless Biotech, Inc. (1) · Akan Biosciences, LLC (1) · Boston University (1) · Cellcolabs Clinical SPV Limited (1) · Eli Lilly and Company (1) · Genascence Corporation (1) · Hawler Medical University (1) · Levicept (1) · Mayo Clinic (1) · Purdue Pharma LP (1) · Queen Savang Vadhana Memorial Hospital, Thailand (1) · Rasmia Elgohary (1) · Rehasport Clinic (1) · Sadat City University (1)
United States (9) · Egypt (2) · Poland (2) · Canada (1) · Czechia (1) · Denmark (1) · Hong Kong (1) · Iraq (1) · Moldova (1) · Puerto Rico (1) · Thailand (1) · United Arab Emirates (1)
George K Lewis, Ph.D. (2) · David Petron, MD (1) · Fahti Yousef, PhD (1) · Fernando E Figueroa, M.D. (1) · Jean Liew, MD MS (1) · Kamel Gado, MD (1) · Niaz Albarzinji, MBCHB,DRMR (1) · Pawel Bakowski, MD PhD (1) · Shane A Shapiro (1) · Simon Westbrook (1) · Surapol Athiprayul, MD (1) · Tomasz Piontek, MD PhD (1)
PMID 12081113, PMID 1991946, PMID 25035839, PMID 25161985, PMID 25925602, PMID 26432430, PMID 28012636, PMID 28386761, PMID 30623236, PMID 30632533, PMID 32434498, PMID 33754800, PMID 34826301, PMID 35103547, PMID 41905364
K23AR082938 (1)